Heater Natalie K, Warrior Surbhi, Lu Janice
Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, 60611, USA.
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N St. Clair, Suite 850, Chicago, IL, 60611, USA.
J Hematol Oncol. 2024 Dec 25;17(1):131. doi: 10.1186/s13045-024-01649-z.
Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both PD-L1 positive metastatic and early-stage triple-negative breast cancer, while ongoing clinical trials seek to expand the current treatment landscape for immune checkpoint inhibitors in hormone receptor positive and HER2 positive breast cancer. Antibody drug conjugates are FDA approved for triple negative and HER2+ disease, and are being studied in combination with immune checkpoint inhibitors. Vaccines and bispecific antibodies are areas of active research. Studies of cellular therapies such as tumor infiltrating lymphocytes, chimeric antigen receptor-T cells and T cell receptor engineered cells are promising and ongoing. This review provides an update of recent major clinical trials of immunotherapy in breast cancer and discusses future directions in the treatment of breast cancer.
乳腺癌免疫治疗领域已取得了重大的治疗进展。免疫检查点抑制剂帕博利珠单抗联合化疗已获得美国食品药品监督管理局（FDA）批准，用于治疗PD-L1阳性转移性和早期三阴性乳腺癌，同时正在进行的临床试验旨在扩大免疫检查点抑制剂在激素受体阳性和HER2阳性乳腺癌中的当前治疗格局。抗体药物偶联物已获得FDA批准用于三阴性和HER2 +疾病，并且正在研究其与免疫检查点抑制剂联合使用的情况。疫苗和双特异性抗体是积极研究的领域。对肿瘤浸润淋巴细胞、嵌合抗原受体T细胞和T细胞受体工程细胞等细胞疗法的研究前景广阔且正在进行中。本综述提供了乳腺癌免疫治疗近期主要临床试验的最新情况，并讨论了乳腺癌治疗的未来方向。
